TB-500 · 5mg vial · research use only
TB-500 dosage, framed as loading and maintenance.
TB-500 is the synthetic active fragment of Thymosin Beta-4, and its dosing in the literature is organised around two phases — an initial loading window followed by a lower maintenance schedule. This page lays out the milligram ranges and twice-weekly cadence reported in research protocols, the reconstitution math for a 5mg lyophilized vial, and the short plasma half-life that contrasts with its longer biological persistence — framed as a research reference, not a human protocol or medical advice.
Loading then maintenance
Research protocols typically split TB-500 into two phases. A loading window runs a higher weekly total — commonly modelled around 5–10 mg per week, split across two administrations — for the first 4–6 weeks. A maintenance phase then drops to a lower weekly total, often around 2–5 mg per week, given once or twice weekly. The two-phase structure reflects how the actin-binding peptide is studied in tissue-repair models.
TB-500 research overview →Reconstitution math, 5mg vial
Titan's TB-500 ships as a 5mg lyophilized vial. Reconstitute with bacteriostatic water: add 1 mL and the whole vial is 5 mg/mL, so 0.5 mL is 2.5 mg and the full mL is 5 mg. Add 2 mL for 2.5 mg/mL and every draw halves in strength. A single 5mg vial covers a maintenance week or roughly half a loading week at the ranges above — confirm against the calculator before any in-vitro work.
Run the numbers →Short plasma life, long persistence
TB-500's measured plasma half-life is short — on the order of a few hours — but its biological persistence in tissue is reported to be considerably longer, which is why research schedules use a twice-weekly rather than daily cadence even though the circulating peptide clears quickly. The mismatch between plasma clearance and functional effect is a defining feature of the compound.
TB-500 half-life →Frequently paired with BPC-157
TB-500 and BPC-157 are studied together across tissue and connective-tissue research, and the two are commonly modelled on parallel schedules — TB-500 twice weekly in milligrams, BPC-157 daily in micrograms. Titan lists them as separate SKUs; the stack page explains how the literature pairs them and the combined discount tiers on multi-item orders.
The BPC-157 / TB-500 pairing →Format and purity to confirm
Titan's TB-500 is a 5mg lyophilized powder with an HPLC main-peak result against a ≥99% internal purity target and mass-spec identity confirmation on a lot-matched release sheet. Confirm both before modelling a loading total — at multi-milligram weekly figures, an impure or mislabelled lot changes the effective amount across the whole phase.
See the testing workflow →Research-use framing
TB-500 has no regulatory approval for human use. The loading and maintenance ranges here are reproduced as a laboratory research reference for in-vitro and modelling work — not instructions for human use. Titan supplies TB-500 strictly as a research reagent, and nothing on this page is medical or dosing advice.
Research-use policy →The detail, in plain terms
The dosing reference, in one table.
TB-500's dosing is organised around a loading phase and a maintenance phase, both in milligrams per week. These are the variables a research protocol actually weighs — reproduced as a reference, not a human protocol.
- Compound
- TB-500 — synthetic active fragment of Thymosin Beta-4.
- Loading range
- ≈5–10 mg/week, split twice weekly, for roughly 4–6 weeks.
- Maintenance range
- ≈2–5 mg/week, once or twice weekly.
- Half-life
- Short plasma half-life (hours); longer biological tissue persistence.
- Format
- 5mg lyophilized vial, $89.99 — reconstitute before in-vitro use.
- Reconstitution
- 1 mL BAC water → 5 mg/mL (0.5 mL = 2.5 mg); 2 mL → 2.5 mg/mL.
Questions researchers ask
Before you order.
- What is the research dosage range for TB-500?
- Research protocols typically model a loading phase of roughly 5–10 mg per week split across two administrations for about 4–6 weeks, followed by a maintenance phase of roughly 2–5 mg per week. These figures come from the research literature on the Thymosin Beta-4 fragment and are reproduced as a laboratory reference, not a human dosing protocol or medical advice.
- Why is TB-500 dosed twice weekly instead of daily?
- TB-500's plasma half-life is only a few hours, but its biological persistence in tissue is reported to be considerably longer. That mismatch is why research schedules use a twice-weekly cadence — the circulating peptide clears quickly, but the functional effect modelled in tissue-repair studies lasts well beyond plasma clearance.
- How do I reconstitute a 5mg TB-500 vial?
- Add bacteriostatic water to the lyophilized powder. Adding 1 mL makes the whole 5mg vial 5 mg/mL, so 0.5 mL is 2.5 mg. Adding 2 mL gives 2.5 mg/mL and halves every draw. Always confirm against the reconstitution calculator before any in-vitro work.
- Can TB-500 and BPC-157 be used together in research?
- They are frequently studied together in tissue and connective-tissue research and commonly modelled on parallel schedules — TB-500 twice weekly in milligrams, BPC-157 daily in micrograms. Titan stocks both as separate SKUs; the BPC-157 / TB-500 stack page covers how the literature pairs them and the multi-item discount tiers.
- Is TB-500 approved for human use?
- No. TB-500 has no regulatory approval for human use. Titan Peptide Lab supplies it strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic, or preventative use.